# A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)

> **NCT00943761** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 45 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Vaniprevir 600 mg b.i.d.
- **DRUG:** Vaniprevir 300 mg b.i.d.
- **DRUG:** Pegylated interferon
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00943761
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-23
- **Primary completion:** 2013-05-29
- **Final completion:** 2013-05-29
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2021-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00943761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00943761, "A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00943761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*